Pfizer, BioNTech report high efficacy of COVID-19 booster shot in study

Pfizer Inc and German partner BioNTech SEĀ on Thursday said data from a Phase III trial demonstrated high efficacy of a booster dose of their COVID-19 vaccine against the virus, including the Delta variant.

They said a trial of 10,000 participants aged 16 or older showed 95.6% effectiveness against the diseases, during a period when the Delta strain was prevalent.

The study also found that the booster shot had a favorable safety profile.

Read Full Story
Reuters Rating

Share this:

Leave a Reply

%d bloggers like this: